产品编号 :
Cas No. :
CAS No. |
931399-19-8 |
|---|---|
中文名称 |
GSK360A(研发代号;非IUPAC系统命名) |
英文名称 |
GSK360A |
别名 |
2-[[1-(2-cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxoquinoline-3-carbonyl]amino]acetic acid | DTXSID10715754 | GSK360A | HY-123422 | N-[1-(2-Cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl]glycine | AKOS040748476 | SCHEMBL8243641 |
标准英文名 |
(1-(2-cyclopropylethyl)-6-fluoro-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbonyl)glycine |
分子式 |
C17H17FN2O5 |
分子量 |
348.33 |
精确分子量 |
348.11 |
SMILES |
O=C(O)CNC(C1=C(O)C2=C(N(CCC3CC3)C1=O)C=CC(F)=C2)=O |
标准SMILES |
OC(=O)CNC(=O)C1C(=O)N(CCC2CC2)C2C=CC(F)=CC=2C=1O |
用途 |
GSK360A is an orally active HIF-PHD inhibitor that activates the HIF-1α pathway and protects the failing heart after myocardial infarction (MI). |
InChIKey |
TYHRZQVUPPODPT-UHFFFAOYSA-N |
|
|
评论 |
|---|